18 Aug 2026
ZERO Biotech Company Limited ("ZERO Biotech") and Grand Pharmaceutical Group Limited ("Grand Pharma", 0512.HK) today announced the formal signing of a Strategic Collaboration Agreement aimed at accelerating the development, translation, and deployment of novel targeted radiopharmaceutical therapies.
The official signing ceremony was hosted at Hong Kong Science and Technology Park (HKSTP), represented by Clement, CEO of ZERO Biotech, and Frank Zhou, CEO of Grand Pharma.
The high-profile ceremony was held in the presence of distinguished leadership representatives from the Hubei Province and InvestHK, highlighting the strategic significance of this cross-boundary biotechnology initiative between Hubei and Hong Kong.
Expanding the Horizons of Precision Theranostics
Under the terms of the agreement, ZERO Biotech and Grand Pharma will establish a collaborative framework to leverage Hong Kong’s strategic role as an international life sciences hub. The partnership will focus on co-developing novel radiopharmaceutical candidates, optimizing local radiolabeling and manufacturing infrastructure, and promoting advanced radioligand therapy (RLT) across regional healthcare centers.
Hong Kong’s robust clinical infrastructure, alignment with international regulatory standards, and strong backing from government bodies like InvestHK position the city as an ideal launchpad for advanced radioligand therapies.
